Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Inventory (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Change in Inventory for 8 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 70.69% year-over-year to $3.4 million, compared with a TTM value of $15.3 million through Dec 2025, down 19.9%, and an annual FY2025 reading of $15.3 million, down 19.9% over the prior year.
  • Change in Inventory was $3.4 million for Q4 2025 at Neurocrine Biosciences, down from $12.3 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $12.3 million in Q3 2025 and bottomed at -$2.9 million in Q3 2023.
  • Average Change in Inventory over 4 years is $2.4 million, with a median of $1.7 million recorded in 2025.
  • The sharpest move saw Change in Inventory surged 1188.89% in 2024, then plummeted 139.62% in 2025.
  • Year by year, Change in Inventory stood at $2.1 million in 2021, then plummeted by 57.14% to $900000.0 in 2023, then soared by 1188.89% to $11.6 million in 2024, then tumbled by 70.69% to $3.4 million in 2025.
  • Business Quant data shows Change in Inventory for NBIX at $3.4 million in Q4 2025, $12.3 million in Q3 2025, and -$2.1 million in Q2 2025.